Article Versions Notes

Waghmare A, Dadhe R, Kobbe R, Danziger-Isakov L, Sprinz E, Muñoz FM, Gayed J, Solan R, Diya O, Abraham B, et al. Safety and Immunogenicity of the BNT162b2 COVID-19 Vaccine in Immunocompromised Participants 2 Years and Older: Results of an Open-Label Phase 2b Study. Vaccines. 2026; 14(7):602. https://doi.org/10.3390/vaccines14070602

Waghmare, Alpana, Rucha Dadhe, Robin Kobbe, Lara Danziger-Isakov, Eduardo Sprinz, Flor M. Muñoz, Juleen Gayed, Rohit Solan, Oyeniyi Diya, Bisrat Abraham, and et al. 2026. "Safety and Immunogenicity of the BNT162b2 COVID-19 Vaccine in Immunocompromised Participants 2 Years and Older: Results of an Open-Label Phase 2b Study" Vaccines 14, no. 7: 602. https://doi.org/10.3390/vaccines14070602

Waghmare, A., Dadhe, R., Kobbe, R., Danziger-Isakov, L., Sprinz, E., Muñoz, F. M., Gayed, J., Solan, R., Diya, O., Abraham, B., Feng, Y., Xu, X., Belanger, T., Mensa, F. J., Girardin, R., Türeci, Ö., Şahin, U., Modjarrad, K., Swanson, K. A., ... Kitchin, N. (2026). Safety and Immunogenicity of the BNT162b2 COVID-19 Vaccine in Immunocompromised Participants 2 Years and Older: Results of an Open-Label Phase 2b Study. Vaccines, 14(7), 602. https://doi.org/10.3390/vaccines14070602